<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2267">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05131646</url>
  </required_header>
  <id_info>
    <org_study_id>CLS1002-102</org_study_id>
    <nct_id>NCT05131646</nct_id>
  </id_info>
  <brief_title>Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study</brief_title>
  <official_title>Extension Study to Evaluate the Long-term Outcomes of Subjects Following CLS-AX Administration for Age-related Macular Degeneration in the CLS-AX CLS1002-101 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clearside Biomedical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clearside Biomedical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, non-interventional extension study of up to 12 weeks in duration in&#xD;
      subjects completing Cohorts 2 and 3 of the Parent study, CLS1002-101.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, non-interventional extension study of up to 12 weeks in duration in&#xD;
      subjects completing Cohorts 2 and 3 of the Parent study, CLS1002-101. The Parent study is a&#xD;
      12-week, Phase 1/2a, multicenter study designed to assess the safety and tolerability of a&#xD;
      single dose of CLS-AX administered suprachoroidally in subjects with neovascular age-related&#xD;
      macular degeneration (nAMD) who show stable visual acuity following 3 or more injections with&#xD;
      an intravitreal (IVT) anti-VEGF therapy in the preceding 5 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The number of subjects experiencing treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>24 weeks</time_frame>
    <description>The number of subjects experiencing treatment-emergent adverse events (TEAEs). Treatment-emergent adverse events are defined as an event that emerges following treatment with CLS-AX (administered at Visit 2 (Baseline, Day 1) of the Parent study, CLS1002-101), having been absent pre-treatment or worsens relative to the pre-treatment state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of subjects experiencing serious adverse events (SAEs)</measure>
    <time_frame>24 weeks</time_frame>
    <description>The number of subjects experiencing serious adverse events (SAEs). Serious adverse events are defined as a serious event that emerges following treatment with CLS-AX (administered at Visit 2 (Baseline, Day 1) of the Parent study, CLS1002-101), having been absent pre-treatment or worsens relative to the pre-treatment state</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in central subfield retinal thickness (CST) in the study eye</measure>
    <time_frame>24 weeks</time_frame>
    <description>Mean change from Baseline in central subfield retinal thickness (CST) in the study eye at Visits 6, 7, and 8 (Weeks 16, 20, and 24). Baseline is defined as the value from Visit 2 (Baseline, Day 1) of the Parent study, CLS1002-101.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in best corrected visual acuity letter score in the study eye</measure>
    <time_frame>24 weeks</time_frame>
    <description>Mean change from Baseline in best corrected visual acuity letter score in the study eye at Visits 6, 7, and 8 (Weeks 16, 20, and 24). Baseline is defined as the value from Visit 2 (Baseline, Day 1) of the Parent study, CLS1002-101.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of subjects receiving additional therapy in the study eye</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number and percentage of subjects receiving additional therapy in the study eye at Visits 5, 6, 7, and 8 (Weeks 12, 16, 20, and 24).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of subjects meeting the additional therapy criteria in the study eye</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number and percentage of subjects meeting the additional therapy criteria in the study eye at Visits 6, 7, and 8 (Week 16, 20, and 24).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in pre injection Intraocular Pressure (IOP)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Changes from Baseline (Visit 2) pre injection IOP values in the study eye</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Cohort 2 (Middle Dose) Extension</arm_group_label>
    <description>Subjects who were administered by suprachoroidal injection 0.10 mg CLS-AX in cohort 2 of the parent study, CLS1002-101, will be followed for an additional 12 weeks following exit from the Parent study. No intervention will be administered in this extension study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (High Dose) Extension</arm_group_label>
    <description>Subjects who were administered by suprachoroidal injection 0.30 mg CLS-AX in cohort 3 of the parent study, CLS1002-101, will be followed for an additional 12 weeks following exit from the Parent study. No intervention will be administered in this extension study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CLS-AX</intervention_name>
    <description>injectable suspension of small molecule tyrosine kinase inhibitor (TKI)</description>
    <arm_group_label>Cohort 2 (Middle Dose) Extension</arm_group_label>
    <arm_group_label>Cohort 3 (High Dose) Extension</arm_group_label>
    <other_name>axitinib injectable suspension</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants who completed cohort 2 or 3 of CLS1002-101&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Enrolled in and completed the Parent study, CLS1002-101, as part of Cohort 2 or Cohort&#xD;
             3.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received prohibited medication in the Parent study, CLS1002-101.&#xD;
&#xD;
          -  Enrolled in the Parent study CLS1002-101 as part of Cohort 1.&#xD;
&#xD;
          -  Females of childbearing potential who are pregnant and or lactating.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Ciulla, MD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Clearside Biomedical, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gina Debrah</last_name>
    <phone>678-254-2345</phone>
    <email>gina.debrah@clearsidebio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Project Manager</last_name>
    <email>oasis.ext@clearsidebio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Retinal Consultants of Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>602-222-2221</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northern California Retina Vitreous Associates Medical Group, LLC</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>650-988-7467</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cumberland Valley Retina Consultants</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>301-665-1712</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Texas</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>713-394-7575</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Texas</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>713-524-3434</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>November 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMD</keyword>
  <keyword>Wet-AMD</keyword>
  <keyword>suprachoroidal</keyword>
  <keyword>tyrosine kinase inhibitor</keyword>
  <keyword>nAMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Axitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

